- JP-listed companies
- OncoTherapy Science, Inc.
- Financials
- Net income margin (%)
OncoTherapy Science, Inc. (4564)
Market cap
¥6.9B
P/E ratio
OncoTherapy Science develops cancer treatments using genetic research, including targeted drugs, immunotherapies, and precision medicine testing for personalized cancer care.
| Period End | Net income margin (%) | YoY (%) |
|---|---|---|
| Mar 31, 2025 | -108.7 | -48.52% |
| Mar 31, 2024 | -211.1 | +114.20% |
| Mar 31, 2023 | -98.6 | -55.78% |
| Mar 31, 2022 | -222.9 | -52.54% |
| Mar 31, 2021 | -469.7 | -33.65% |
| Mar 31, 2020 | -707.9 | -32.32% |
| Mar 31, 2019 | -1,046 | -22.50% |
| Mar 31, 2018 | -1,349.6 | +28.88% |
| Mar 31, 2017 | -1,047.2 | +0.22% |
| Mar 31, 2016 | -1,044.9 | +510.35% |
| Mar 31, 2015 | -171.2 | -54.40% |
| Mar 31, 2014 | -375.4 | +1071.59% |
| Mar 31, 2013 | -32 | -367.66% |
| Mar 31, 2012 | 12 |